Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Urinary Tract Infection

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    July 2018
  1. HOWARD JC, Anderson T, Creighton J, Freeman JT, et al
    Geographical and temporal clustering of OXA-48-producing Escherichia coli ST410 causing community-onset urinary tract infection in Christchurch, New Zealand.
    J Antimicrob Chemother. 2018 Jul 3. pii: 5048317. doi: 10.1093.
    PubMed     Text format    


    June 2018
  2. BOLLESTAD M, Grude N, Solhaug S, Raffelsberger N, et al
    Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
    J Antimicrob Chemother. 2018 Jun 29. pii: 5046991. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  3. NYGAARD JENSEN J, Melander E, Hedin K, Bjerrum L, et al
    Comparison of antibiotic prescribing and antimicrobial resistance in urinary tract infections at the municipal level among women in two Nordic regions.
    J Antimicrob Chemother. 2018 May 10. pii: 4995081. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  4. ALEXANDRE K, Reveillon-Istin M, Fabre R, Delbos V, et al
    Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods.
    J Antimicrob Chemother. 2018 Apr 6. pii: 4964016. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  5. MARQUES C, Belas A, Franco A, Aboim C, et al
    Increase in antimicrobial resistance and emergence of major international high-risk clonal lineages in dogs and cats with urinary tract infection: 16 year retrospective study.
    J Antimicrob Chemother. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  6. FRANSEN F, Melchers MJB, Lagarde CMC, Meletiadis J, et al
    Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections.
    J Antimicrob Chemother. 2017 Sep 11. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  7. SIMS M, Mariyanovski V, McLeroth P, Akers W, et al
    Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. SHALLCROSS L, Beckley N, Rait G, Hayward A, et al
    Antibiotic prescribing frequency amongst patients in primary care: a cohort study using electronic health records.
    J Antimicrob Chemother. 2017;72:1818-1824.
    PubMed     Text format     Abstract available


    May 2017
  9. PFALLER MA, Bassetti M, Duncan LR, Castanheira M, et al
    Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    J Antimicrob Chemother. 2017;72:1386-1395.
    PubMed     Text format     Abstract available


    January 2017
  10. SUGIANLI AK, Ginting F, Kusumawati RL, Pranggono EH, et al
    Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia.
    J Antimicrob Chemother. 2017 Jan 30. pii: dkw578. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. KOKSAL I, Yilmaz G, Unal S, Zarakolu P, et al
    Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
    J Antimicrob Chemother. 2017 Jan 25. pii: dkw574. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. STONE GG, Bradford PA, Yates K, Newell P, et al
    In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    J Antimicrob Chemother. 2017 Jan 14. pii: dkw561. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. ROSELLO A, Hayward AC, Hopkins S, Horner C, et al
    Impact of long-term care facility residence on the antibiotic resistance of urinary tract Escherichia coli and Klebsiella.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw555. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. POPEJOY MW, Paterson DL, Cloutier D, Huntington JA, et al
    Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    J Antimicrob Chemother. 2017;72:268-272.
    PubMed     Text format     Abstract available


    December 2016
  15. STALEY C, Vaughn BP, Graiziger CT, Sadowsky MJ, et al
    Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw499. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. KULLAR R, Wagenlehner FM, Popejoy MW, Long J, et al
    Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw486. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  17. JEAN SS, Hsueh PR
    Distribution of ESBLs, AmpC beta-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the Study for Monitoring Antimicrobial Resist
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    September 2016
  18. SCHMIDT K, Mwaigwisya S, Crossman LC, Doumith M, et al
    Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  19. MULDER M, Kiefte-de Jong JC, Goessens WH, de Visser H, et al
    Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    August 2016
  20. DELISLE G, Quach C, Domingo MC, Boudreault AA, et al
    Escherichia coli antimicrobial susceptibility profile and cumulative antibiogram to guide empirical treatment of uncomplicated urinary tract infections in women in the province of Quebec, 2010-15.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    June 2016
  21. CHIN TL, McNulty C, Beck C, MacGowan A, et al
    Antimicrobial resistance surveillance in urinary tract infections in primary care.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  22. FRANSEN F, Melchers MJ, Meletiadis J, Mouton JW, et al
    Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    May 2016
  23. SEROY JT, Grim SA, Reid GE, Wellington T, et al
    Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  24. FREIRE MP, de Oliveira Garcia D, Cury AP, Spadao F, et al
    Outbreak of IMP-producing carbapenem-resistant Enterobacter gergoviae among kidney transplant recipients.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    March 2016
  25. HUNTINGTON JA, Sakoulas G, Umeh O, Cloutier DJ, et al
    Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    September 2015
  26. TREVINO SE, Babcock HM, Henderson JP, Lane MA, et al
    Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    August 2015
  27. NOMAMIUKOR BO, Horner C, Kirby A, Hughes GJ, et al
    Living conditions are associated with increased antibiotic resistance in community isolates of Escherichia coli.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    July 2015
  28. ALGHORIBI MF, Gibreel TM, Farnham G, Al Johani SM, et al
    Antibiotic-resistant ST38, ST131 and ST405 strains are the leading uropathogenic Escherichia coli clones in Riyadh, Saudi Arabia.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  29. VERVOORT J, Xavier BB, Stewardson A, Coenen S, et al
    Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota.
    J Antimicrob Chemother. 2015;70:1989-92.
    PubMed     Text format     Abstract available


    April 2015
  30. KOMP LINDGREN P, Klockars O, Malmberg C, Cars O, et al
    Pharmacodynamic studies of nitrofurantoin against common uropathogens.
    J Antimicrob Chemother. 2015;70:1076-82.
    PubMed     Text format     Abstract available


    March 2015
  31. CHIN TL, MacGowan AP, Bowker KE, Elder F, et al
    Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England.
    J Antimicrob Chemother. 2015.
    PubMed     Text format    


  32. IRONMONGER D, Edeghere O, Bains A, Loy R, et al
    Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    January 2015
  33. RATTANAUMPAWAN P, Nachamkin I, Bilker WB, Roy JA, et al
    Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  34. SOUBIROU JF, Rossi B, Couffignal C, Ruppe E, et al
    Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  35. CICCOLINI M, Spoorenberg V, Geerlings SE, Prins JM, et al
    Using an index-based approach to assess the population-level appropriateness of empirical antibiotic therapy.
    J Antimicrob Chemother. 2015;70:286-93.
    PubMed     Text format     Abstract available


    December 2014
  36. VAN DUIN D, Cober E, Richter SS, Perez F, et al
    Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.
    J Antimicrob Chemother. 2014.
    PubMed     Text format     Abstract available


    July 2014
  37. PORRES-OSANTE N, Azcona-Gutierrez JM, Rojo-Bezares B, Undabeitia E, et al
    Emergence of a multiresistant KPC-3 and VIM-1 carbapenemase-producing Escherichia coli strain in Spain.
    J Antimicrob Chemother. 2014;69:1792-5.
    PubMed     Text format     Abstract available


    June 2014
  38. DEMONCHY E, Dufour JC, Gaudart J, Cervetti E, et al
    Impact of a computerized decision support system on compliance with guidelines on antibiotics prescribed for urinary tract infections in emergency departments: a multicentre prospective before-and-after controlled interventional study.
    J Antimicrob Chemother. 2014.
    PubMed     Text format     Abstract available


    May 2014
  39. BRUST K, Evans A, Plemmons R
    Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review.
    J Antimicrob Chemother. 2014.
    PubMed     Text format     Abstract available


  40. BRUST K, Evans A, Plemmons R
    Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline.
    J Antimicrob Chemother. 2014.
    PubMed     Text format    


    February 2014
  41. HWANG TJ, Hooper DC
    Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study.
    J Antimicrob Chemother. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Urinary Tract Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: